Patients with non-resectable Non-small Cell Lung Cancer will receive thoracic radiation therapy 60-70 Gy over 30-35 fractions and concurrent with Erlotinib 150mg/day. Followed by Erlotinib 150 mg/day consolidation treatment.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma, large cell carcinoma and etc)
Tumor EGFR mutation
Presence of measurable disease by RECIST
stage IIIA or IIIB, non-resectable
ECOG performance status 0-2
No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital.
You may not be if
Carcinoid tumor, small cell carcinoma of lung
Patients with any distant metastasis
History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
Any other morbidity or situation with contraindication for radiotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment)
Pregnant or lactating women, women who has not taken test of pregnancy (within 7 days before the first administration) and pregnant women
Women and men of childbearing potential who have no willing of employing adequate contraception
Tumor EGFR wild
Clareo Health | Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
